Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Candiolo – page 65

987 clinical trials in Candiolo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Candiolo at a glance
987
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

987 trials in Candiolo

Open in trial search

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:PTC Therapeutics Inc.

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neuroblastoma+4

Not recruiting

Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ribociclib
  • Sponsor:Novartis Pharma AG

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Upstream Bio Inc.

Study of Mogamulizumab and Total Skin Electron Beam Therapy for Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mogamulizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Candiolo

What the registry says about research in the country

01 Hematologic Malignancies

Advanced research focusing on blood cancers including innovative treatments for myelodysplastic syndromes, follicular lymphoma, and chronic myelomonocytic leukemia. Studies evaluate novel drug combinations and maintenance therapies to improve patient outcomes.

  • Multiple Myeloma Treatment Optimization
  • Lymphoma Therapy Innovations
  • Leukemia Treatment Strategies

Trials investigate targeted therapies and immunotherapy approaches for better disease management.

02 Solid Tumors

Comprehensive research on lung cancer, breast cancer, and colorectal cancer. Studies explore combination therapies involving immunotherapy, targeted agents, and conventional treatments to enhance treatment efficacy.

  • Advanced NSCLC Treatments
  • Metastatic Disease Management
  • Novel Drug Combinations

Focus on personalized medicine approaches and biomarker-driven treatment selection.

03 Rare Cancers

Dedicated research into sarcomas, head and neck cancers, and other rare malignancies. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Osteosarcoma Treatments
  • Soft Tissue Sarcoma Therapy
  • Innovative Treatment Protocols

Emphasis on developing effective treatments for cancers with limited therapeutic options.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.